Skip to content

Investors

Investors

Company Profile

Arena is a biopharmaceutical company focused on discovering and developing novel, small molecule drugs. We are currently directing our activities and resources primarily on:

Stock Quote

Copyright Nasdaq. Minimum 15 minutes delayed.

Events & Presentations
Annual Report and Proxy Statement
Date Title and Summary
Toggle Summary Eisai Inc. Announces Positive Topline Results from CAMELLIA-TIMI61, a Large-Scale Cardiovascular Outcome Trial for the Anti-Obesity Agent BELVIQ
<p><strong>WOODCLIFF LAKE, N.J., JULY 17, 2018 – </strong>Eisai Inc. announced positive topline results from the <a href="https://clinicaltrials.gov/ct2/show/NCT02019264">CAMELLIA-TIMI 61</a> cardiovascular outcome trial. This 12,000 patient study of BELVIQ<strong><sup>®</sup></strong> (lorcaserin HCl) CIV 10 mg twice-daily was conducted at over 400 sites in eight countries including the United States in collaboration with the Thrombolysis in Myocardial Infarction (TIMI) Study Group and is the largest cardiovascular (CV) outcome trial to date for a weight loss medication.</p>
Toggle Summary Arena Pharmaceuticals Appoints Life Sciences Industry Veteran Kieran T. Gallahue to Board of Directors
SAN DIEGO , July 10, 2018 /PRNewswire/ --&nbsp; Arena Pharmaceuticals, Inc. (Nasdaq: ARNA), a biopharmaceutical company focused on delivering novel, transformational medicines across multiple therapeutic areas, today announced the appointment of Kieran T. Gallahue as a non-executive director. Mr.